7月31日 - ** 手术设备制造商TeleflexTFX.N股价盘前上涨14.2%至130.03美元
** 公司将全年调整后收入增长率预期从1%至2%上调至7.70%至8.70%,反映了对BIOTRONIK血管介入业务的收购。
** 预计收购将在 2025 年下半年带来 2.04 亿美元的收入
** 还将2025年调整后每股收益预期从13.20美元至13.60美元上调至13.90美元至14.30美元
** 分析师预期每股利润为 13.37 美元
** 本季度公司调整后利润为 3.73 美元,预期为 3.36 美元
** 截至上次收盘,股价累计下跌 36
(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.